This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Tumours of skin, Subject name: Dental
[{'content': 'Which of the following is FDA approved Anti-CTLA-4 immunotherapy agent for the treatment of metastatic melanoma? \nSelect and explain. \nA. Nivolumab, B. Lambrolizumab, C. Ipilimumab, D. Trametinib', 'role': 'user'}, {'content': 'Answer: C \nExplanation: TREATMENT OPTIONS FOR METASTATIC MELANOMA - Surgery: Metastasectomy for small number of lesions Immunotherapy: - Interleukin-2 - Immune checkpoint blockade FDA approved - Anti-CTLA-4: Ipilimumab Experimental - Anti-PD-1: Nivolumab, Lambrolizumab (Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2 Molecular targeted therapy: - BRAF inhibitor: Vemurafenib, Dabrafenib - MEK inhibitor: Trametinib', 'role': 'assistant'}]